Precision BioSciences Inc (DTIL)

Currency in USD
7.1300
-0.1000(-1.38%)
Real-time Data·
DTIL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.96007.4200
52 wk Range
3.53008.8200
Key Statistics
Prev. Close
7.23
Open
7.3
Day's Range
6.96-7.42
52 wk Range
3.53-8.82
Volume
97.05K
Average Vol. (3m)
273.04K
1-Year Change
29.1667%
Book Value / Share
3.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DTIL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
32.0000
Upside
+348.81%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Precision BioSciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Precision BioSciences Inc SWOT Analysis


Analyst Outlook
BMO Capital Markets maintains a Market Perform rating with a $34 price target, reflecting cautious optimism about the company's future prospects
Competitive Edge?
Explore how Precision BioSciences aims to differentiate itself in the crowded gene editing market, with upcoming clinical readouts potentially validating its technology
Financial Runway
With $140 million in cash, the company has funding until 2026, but faces challenges in improving investor sentiment amidst recent strategic shifts
ARCUS Innovation
Precision BioSciences' proprietary gene editing platform shows promise in HBV treatment, with clinical trials on the horizon for its lead program PBGENE-HBV
Read full SWOT analysis

Compare DTIL to Peers and Sector

Metrics to compare
DTIL
Peers
Sector
Relationship
P/E Ratio
−4.0x7.9x−0.5x
PEG Ratio
0.01−0.340.00
Price / Book
2.0x2.9x2.6x
Price / LTM Sales
5.4x2.7x3.2x
Upside (Analyst Target)
238.9%428.4%47.6%
Fair Value Upside
Unlock30.3%6.1%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 32.0000
(+348.81% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jones Trading
Buy30.00+320.76%-MaintainMar 18, 2026
Jefferies
Buy19.00+166.48%21.00MaintainMar 13, 2026

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
1.01 / -0.68
Revenue / Forecast
34.2M / --
EPS Revisions
Last 90 days

DTIL Income Statement

People Also Watch

198.39
AVAV
+1.99%
180.44
AXSM
-2.03%
54.73
TEM
+10.49%
55.27
BMRN
-0.36%
430.43
SPGI
+1.22%

FAQ

What Is the Precision BioSciences (DTIL) Stock Price Today?

The Precision BioSciences stock price today is 7.1300 USD.

What Stock Exchange Does Precision BioSciences Trade On?

Precision BioSciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Precision BioSciences?

The stock symbol for Precision BioSciences is "DTIL."

What Is the Precision BioSciences Market Cap?

As of today, Precision BioSciences market cap is 184.2300M USD.

What Is Precision BioSciences's Earnings Per Share (TTM)?

The Precision BioSciences EPS (TTM) is -3.6339.

From a Technical Analysis Perspective, Is DTIL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Precision BioSciences Stock Split?

Precision BioSciences has split 1 times.

How Many Employees Does Precision BioSciences Have?

Precision BioSciences has 68 employees.

What is the current trading status of Precision BioSciences (DTIL)?

As of Apr 15, 2026, Precision BioSciences (DTIL) is trading at a price of 7.1300 USD, with a previous close of 7.2300 USD. The stock has fluctuated within a day range of 6.9600 USD to 7.4200 USD, while its 52-week range spans from 3.5300 USD to 8.8200 USD.

What Is Precision BioSciences (DTIL) Price Target According to Analysts?

The average 12-month price target for Precision BioSciences is 32.0000 USD, with a high estimate of 60 USD and a low estimate of 19 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +348.81% Upside potential.

What Is the DTIL Premarket Price?

DTIL's last pre-market stock price is 7.4308 USD. The pre-market share volume is 3,190.0000, and the stock has decreased by 0.2008, or 2.7800%.

What Is the DTIL After Hours Price?

DTIL's last after hours stock price is 7.3000 USD, the stock has decreased by 0.0700, or 0.9700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.